Skip to main content

A Shift from Class I to Class III Drugs in the Medical Treatment of Arrhythmias: Wishful Thinking?

  • Chapter
Antiarrhythmic Drugs
  • 156 Accesses

Abstract

Recently attention among clinicians and arthythmologists has shifted from the study of class I drugs acting on the Na+ channel to class III drugs or drugs prolonging the action potential duration. The immediate reason was the Cardiac Arrhythmia Suppression Trial (CAST) study (1989), which showed an increased mortality in patients treated for premature ventricular extrasystoles following myocardial infarction with drugs representative of the class I type [2]. The fundamental question that should be answered is whether better results may be expected from the new approach of using drugs prolonging the action potential duration. Is this new hope justified?

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Campbell DL, Qu Y, Rasmusson RL, Strauss HC (1993) The calcium-independent transient outward potassium current in isolated ferret right ventricular myocytes. II Closed state reverse use-dependent block by 4-aminopyridine. J Gen Physiol 101: 603–626

    Google Scholar 

  2. Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989) Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321: 406–412

    Google Scholar 

  3. Carlsson L, Abrahamsson C, Almgren O, Lundberg C, Duker G (1991) Prolonged action potential duration and positive inotropy induced by the novel class III antiarrhythmic agent H234/o9 (almokalant) in isolated human ventricular muscle. J Cardiovasc Pharmacol 18: 882–887

    Article  PubMed  CAS  Google Scholar 

  4. Carmeliet E (1992) Voltage-and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther 262: 809–817

    PubMed  CAS  Google Scholar 

  5. Carmeliet E (1993a) Use-dependent block and use-dependent unblock of the delayed rectifier K+ current by almokalant in rabbit ventricular myocytes. Circ Res 73:857–868

    Google Scholar 

  6. Carmeliet E (1993b) Use-dependent block of the delayed K+ current in rabbit ventricular myocytes. Cardiovasc Drugs Ther 7:599-604

    Google Scholar 

  7. Colatsky TJ, Follmer CH, Starmer CF (1990) Channel specificity in antiarrhythmic drug action: mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation 82: 2235–2242

    Article  PubMed  CAS  Google Scholar 

  8. Hondeghem LM (1991) Ideal antiarrhythmic agents: chemical defibrillators. J Cardiovasc Electrophysiol 2 [Suppl 1: S169 – S177

    Google Scholar 

  9. Hondeghem LM (1992) Development of class III antiarrhythmic agents. J Cardiovasc Pharmacol 20 [Suppl 21: S17 – S22

    Article  Google Scholar 

  10. Jurkiewicz NK, Sanguinetti MC (1993) Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circ Res 72: 75–83

    Google Scholar 

  11. Opthof T, Coronel R, Vermeulen JT, Verberne HJ, van Capelle FJL, Janse MJ (1993) Dispersion of refractoriness in normal and ischaemic canine ventricle: effect of sympathetic stimulation. Cardiovasc Res 27:1954–1960

    Google Scholar 

  12. Sanguinetti MC, Jurkiewicz NK (1990) Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 96: 195–215

    Google Scholar 

  13. Starmer CF, Lastra AA, Nesterenko VV, Grant AO (1991) Proarhythmic response to sodium channel blockade. Theoretical model and numerical experiments. Circulation 84: 1364–1377

    Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Carmeliet, E. (1995). A Shift from Class I to Class III Drugs in the Medical Treatment of Arrhythmias: Wishful Thinking?. In: Breithardt, G., Borggrefe, M., Camm, A.J., Shenasa, M., Haverkamp, W., Hindricks, G. (eds) Antiarrhythmic Drugs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-85624-2_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-85624-2_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-85626-6

  • Online ISBN: 978-3-642-85624-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics